These results suggest that glucose-promoted PEP and/or PEPCK-M activity could have an impact on inflammation, colon cancer progression, and metastasis through the transactivation of PTGS2 and IL6 by the PEP/Ca2+/NFAT signaling pathway. The gene discussed is IL6; the disease is malignant colon neoplasm.